TALG
Intellectual Property & Life Sciences
Business Transactions & Disputes
Biotechnology & FDA Compliance
cGMP Compliance
FDA-510K & PMA Filings
Capital Markets
Mediation Services
Family Law
Real Estate
Industries Served
A Track record of success
TALG’s record of success includes consummating over $50 Billion worth of transactions over the course of 17 years. In the Courtroom, we’ve successfully obtained substantial verdicts in favor of our clients. On the defense side, we’ve saved our clients over $100 Million through a hybrid approach of aggressive advocacy while utilizing cutting edge technologies.
Irvine Office
Las Vegas Office
Dallas Office
Scottsdale Office
Raleigh Office
From Our Clients
News
TALG’s California Employment Law Update of 2022
In California many new pieces of employment legislation were passed this year, and will take effect on January 1, 2023.
The Corporate Transparency Act: Preparing for (Potentially) Onerous Reporting Requirements
Once the Corporate Transparency Act regulations become effective it will effect corporate entities. Now is the time to prepare.
The Capital Raise – Best Practices for Biotech
Biotech and life-science companies are often in need of appropriate capital to execute the company’s mission.
The Ripple Effect of Ripple – When is a Cryptocurrency a Security?
The SEC brought an action against Ripple Labs, Inc. in a crypto-currency litigation case pending before the US District Court.
Clinical Trials – Protection of Human Subjects and the Role of Institutional Review Boards (IRB)
In the second part of the clinical trials series, we examine the duties and obligations of Sponsors and Clinical Research Organizations (CRO) as it relates to the protection of human subjects who participate in clinical trials.
How to Avoid Anti-Corporate Bias by Jurors
Using likeability to a corporation’s advantage increases your chances of trial success.
Clinical Research Organizations (CRO) – Patient Recruitment & Privacy Considerations
In the selection of a Clinical Research Organization (CRO), the Sponsor must ensure that the CRO has careful policies and procedures in place to safeguard protected patient information.
FDA Issues NDA and BLA Recommendations Warranting RTOR
FDA issues guidance and recommendations for New Drug Applications (NDA) and Biologic Laboratory Applications (BLA) which implicate oncology therapies and warrant Real time Oncology Review (RTOR).
FDA Provides GUDID Submission Requirements Guidance
FDA guidance regarding consumer health products and the enforcement of Global Unique Device Identification Database submission requirements.